U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07243704) titled 'Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage' on Nov. 17.
Brief Summary: BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged >=18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of the trial for preventing MACE. Recruitment duration is for 2.5 years. The duration of the medication and follow-up will vary based on your recruitment timeline. If recruited during the first year of the trial, the pati...